Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.
Marketing Status Prescription; Discontinued
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
TTD Drug ID D0W0BF
NDC Product Code 63850-6527; 0395-8157; 68554-0026; 0310-0201; 71335-1879; 65129-1119; 16729-035; 68071-1682; 71052-248; 72789-008; 65096-0117; 51991-620; 59651-236; 65072-0702; 63629-5269; 16571-421; 63850-0010; 82393-201; 62135-490; 63187-080; 62559-670; 50090-2453; 58623-0041; 55111-814; 68382-209; 51927-4435; 68001-155; 50090-5002; 65841-743; 76420-004; 50268-075; 0093-7536; 61200-104; 42291-085; 46014-1160; 70518-2484; 73377-120; 69988-0013; 50090-5812; 62756-428; 62157-077; 70934-488; 70518-2420; 60429-286; 68071-5203; 60687-112; 51552-1568; 46014-1009; 38779-2555; 0904-6195; 43063-383; 60440-2921; 53104-7627; 62175-710
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
SMILES CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiovascular disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
OsteoporosisAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
Urogenital disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Transient ischaemic attack24.04.06.005; 17.08.04.0010.001886%
Tremor17.01.06.002--
Trigger finger15.07.01.0050.003017%Not Available
Tumour flare16.32.03.001--Not Available
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.000197%
Ulcer08.03.06.001--Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.001886%
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Uterine cancer21.07.02.003; 16.12.05.0010.001508%Not Available
Uterine leiomyoma21.07.02.004; 16.04.02.0010.001508%Not Available
Uterine prolapse21.07.05.0060.000754%Not Available
Uveitis06.04.03.003; 10.02.01.0230.003394%
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.0050.001508%
Vaginal infection11.01.10.002; 21.14.02.002--
Vaginal inflammation21.14.02.001--
Vasculitis24.05.02.001; 10.02.02.0060.001508%
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.0030.002640%
Vision blurred17.17.01.010; 06.02.06.0070.002640%
Visual acuity reduced17.17.01.011; 06.02.03.0010.000754%
Visual field defect17.17.01.001; 06.02.07.0030.000754%Not Available
Visual impairment06.02.06.0080.003017%Not Available
Vitreous detachment12.01.04.005; 06.09.01.0020.001508%Not Available
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.0030.000754%
Vulvovaginitis21.14.02.005; 11.01.10.003--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.0060.004902%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 16 Pages